当前位置: 首页 >> 检索结果
301. Integrating Community Health Workers into Community-Based Primary Care Practice Settings to Improve Blood Pressure Control Among South Asian Immigrants in New York City: Results from a Randomized Control Trial.
作者: Nadia S Islam.;Laura C Wyatt.;Shahmir H Ali.;Jennifer M Zanowiak.;Sadia Mohaimin.;Keith Goldfeld.;Priscilla Lopez.;Rashi Kumar.;Susan Beane.;Lorna E Thorpe.;Chau Trinh-Shevrin.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷3期e009321页
Blood pressure (BP) control is suboptimal in minority communities, including Asian populations. We evaluate the feasibility, adoption, and effectiveness of an integrated CHW-led health coaching and practice-level intervention to improve hypertension control among South Asian patients in New York City, Project IMPACT (Integrating Million Hearts for Provider and Community Transformation). The primary outcome was BP control, and secondary outcomes were systolic BP and diastolic BP at 6-month follow-up.
302. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
作者: Truman J Milling.;Saskia Middeldorp.;Lizhen Xu.;Bruce Koch.;Andrew Demchuk.;John W Eikelboom.;Peter Verhamme.;Alexander T Cohen.;Jan Beyer-Westendorf.;C Michael Gibson.;Jose Lopez-Sendon.;Mark Crowther.;Ashkan Shoamanesh.;Michiel Coppens.;Jeannot Schmidt.;Pierre Albaladejo.;Stuart J Connolly.; .
来源: Circulation. 2023年147卷13期1026-1038页
Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation Effects of Factor Xa Inhibitors) was a multicenter, prospective, phase-3b/4, single-group cohort study that evaluated andexanet alfa in patients with acute major bleeding. The results of the final analyses are presented.
303. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
作者: Hertzel C Gerstein.;Zhuoru Li.;Chinthanie Ramasundarahettige.;Seungjae Baek.;Kelley R H Branch.;Stefano Del Prato.;Carolyn S P Lam.;Renato D Lopes.;Richard Pratley.;Julio Rosenstock.;Naveed Sattar.
来源: Circulation. 2023年147卷13期1004-1013页
In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovascular events (MACE) in people with type 2 diabetes at high cardiovascular risk. Whether these benefits are dose related remains uncertain.
304. Association Between Achieved Low-Density Lipoprotein Cholesterol Levels and Long-Term Cardiovascular and Safety Outcomes: An Analysis of FOURIER-OLE.
作者: Prakriti Gaba.;Michelle L O'Donoghue.;Jeong-Gun Park.;Stephen D Wiviott.;Dan Atar.;Julia F Kuder.;KyungAh Im.;Sabina A Murphy.;Gaetano M De Ferrari.;Zbigniew A Gaciong.;Kalman Toth.;Ioanna Gouni-Berthold.;Jose Lopez-Miranda.;François Schiele.;François Mach.;Jose H Flores-Arredondo.;J Antonio G López.;Mary Elliott-Davey.;Bei Wang.;Maria Laura Monsalvo.;Siddique Abbasi.;Robert P Giugliano.;Marc S Sabatine.
来源: Circulation. 2023年147卷16期1192-1203页
Low-density lipoprotein cholesterol (LDL-C) is a well-established risk factor for atherosclerotic cardiovascular disease. However, the optimal achieved LDL-C level with regard to efficacy and safety in the long term remains unknown.
305. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial.
作者: Kirstine Nørregaard Hansen.;Lisette Okkels Jensen.;Michael Maeng.;Martin Kirk Christensen.;Manijeh Noori.;Johnny Kahlert.;Lars Jakobsen.;Anders Junker.;Phillip Freeman.;Julia Ellert-Gregersen.;Bent Raungaard.;Christian Juhl Terkelsen.;Karsten Tange Veien.;Evald Høj Christiansen.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012332页
Biodegradable polymer drug-eluting stents were developed to improve safety and efficacy outcomes for patients undergoing percutaneous coronary intervention. However, few long-term follow-up efficacy studies are available. The study sought to investigate 5-year results from the SORT OUT VII trial (Scandinavian Organization for Randomized Trials With Clinical Outcome) comparing the biodegradable polymer ultrathin-strut sirolimus-eluting Orsiro stent (O-SES) versus the biodegradable polymer biolimus-eluting Nobori stent (N-BES).
306. Baseline Characteristics of Pediatric Patients With Heart Failure Due to Systemic Left Ventricular Systolic Dysfunction in the PANORAMA-HF Trial.
作者: Robert Shaddy.;Michael Burch.;Paul F Kantor.;Susan Solar-Yohay.;Tania Garito.;Sijia Zhang.;Michele Kocun.;Damien Bonnet.
来源: Circ Heart Fail. 2023年16卷3期e009816页
Sacubitril/valsartan has been approved for the management of heart failure (HF) with reduced ejection fraction in adults. PANORAMA-HF trial (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) investigated its effects on clinical outcomes in pediatric patients with HF.
307. Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial.
作者: Chetan P Huded.;Suzanne V Arnold.;Adnan K Chhatriwalla.;John T Saxon.;Samir Kapadia.;Xiao Yu.;John G Webb.;Vinod H Thourani.;Susheel K Kodali.;Craig R Smith.;Michael J Mack.;Martin B Leon.;David J Cohen.
来源: Circ Cardiovasc Interv. 2022年15卷12期e012195页
Rehospitalization is a common end point in clinical trials of structural heart interventions, but whether rehospitalization is clinically and prognostically relevant in these patients is uncertain. The aim of this study was to evaluate the risk of rehospitalization events after aortic valve replacement (AVR) and their association with mortality and health status.
308. Challenging the Hemodynamic Hypothesis in Heart Failure With Preserved Ejection Fraction: Is Exercise Capacity Limited by Elevated Pulmonary Capillary Wedge Pressure?
作者: Satyam Sarma.;James P MacNamara.;Bryce N Balmain.;Christopher M Hearon.;Denis J Wakeham.;Andrew R Tomlinson.;Linda S Hynan.;Tony G Babb.;Benjamin D Levine.
来源: Circulation. 2023年147卷5期378-387页
Exercise intolerance is a defining characteristic of heart failure with preserved ejection fraction (HFpEF). A marked rise in pulmonary capillary wedge pressure (PCWP) during exertion is pathognomonic for HFpEF and is thought to be a key cause of exercise intolerance. If true, acutely lowering PCWP should improve exercise capacity. To test this hypothesis, we evaluated peak exercise capacity with and without nitroglycerin to acutely lower PCWP during exercise in patients with HFpEF.
309. Gut Microbiota-Generated Phenylacetylglutamine and Heart Failure.
作者: Kymberleigh A Romano.;Ina Nemet.;Prasenjit Prasad Saha.;Arash Haghikia.;Xinmin S Li.;Maradumane L Mohan.;Beth Lovano.;Laurie Castel.;Marco Witkowski.;Jennifer A Buffa.;Yu Sun.;Lin Li.;Christopher M Menge.;Ilja Demuth.;Maximilian König.;Elisabeth Steinhagen-Thiessen.;Joseph A DiDonato.;Arjun Deb.;Fredrik Bäckhed.;W H Wilson Tang.;Sathyamangla Venkata Naga Prasad.;Ulf Landmesser.;David R Van Wagoner.;Stanley L Hazen.
来源: Circ Heart Fail. 2023年16卷1期e009972页
The gut microbiota-dependent metabolite phenylacetylgutamine (PAGln) is both associated with atherothrombotic heart disease in humans, and mechanistically linked to cardiovascular disease pathogenesis in animal models via modulation of adrenergic receptor signaling.
310. Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study.
作者: Calum A MacRae.;Matthew R G Taylor.;Luisa Mestroni.;John Moses.;Euan A Ashley.;Matthew T Wheeler.;Neal K Lakdawala.;Ray E Hershberger.;Victor Sandor.;Michael E Saunders.;Colleen Oliver.;Patrice A Lee.;Daniel P Judge.
来源: Circ Genom Precis Med. 2023年16卷1期e003730页
Lamin A/C gene (LMNA)-related dilated cardiomyopathy is a serious and life-threatening condition with a high unmet medical need. This phase 2 study assessed the effects of the oral selective p38 mitogen-activated protein kinase inhibitor ARRY-371797 on functional capacity and cardiac function in patients with LMNA-related dilated cardiomyopathy.
311. Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.
作者: Rosalie A Scholtes.;Anne C Hesp.;Charlotte M Mosterd.;Frank Geurts.;Ewout J Hoorn.;Daan J Touw.;Merle M Krebber.;Jaap A Joles.;Hiddo J L Heerspink.;Daniël H van Raalte.
来源: Circulation. 2022年146卷24期1895-1897页 312. BioMatrix Versus Orsiro Stents for Coronary Artery Disease: A Multicenter, Randomized, Open-Label Study.
作者: Chang-Hwan Yoon.;Ju-Seung Kwun.;Young Jin Choi.;Jin Joo Park.;Si-Hyuck Kang.;Sun-Hwa Kim.;Jung-Won Suh.;Tae-Jin Youn.;Myeong-Kon Kim.;Kwang Soo Cha.;Seung-Hwan Lee.;Bum-Kee Hong.;Seung-Woon Rha.;Woong Chol Kang.;Jae-Hwan Lee.;Sang-Hyun Kim.;In-Ho Chae.
来源: Circ Cardiovasc Interv. 2023年16卷1期e012307页
Comparative studies of ultrathin-strut biodegradable polymer sirolimus-eluting stent (BP-SES) have reported promising results and validated its excellent outcomes in terms of safety and efficacy. However, there are limited studies comparing BP drug-eluting stents with struts of different thicknesses. We compared the long-term clinical outcomes of patients treated with an ultrathin-strut BP-SES or a thick-strut biodegradable polymer biolimus-eluting stent (BP-BES).
313. First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
作者: Bruce S Stambler.;Francis Plat.;Philip T Sager.;Silvia Shardonofsky.;Douglas Wight.;Diane Potvin.;A Shekhar Pandey.;James E Ip.;Benoit Coutu.;Blandine Mondésert.;Laurence D Sterns.;Matthew Bennett.;Jeffrey L Anderson.;Roger Damle.;Ronald Haberman.;A John Camm.
来源: Circ Arrhythm Electrophysiol. 2022年15卷12期e010915页
Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medically supervised intervention. Intranasal etripamil, is an investigational fast-acting, nondihydropyridine, L-type calcium channel blocker, designed for unsupervised self-administration to terminate atrioventricular nodal-dependent PSVT. Phase 2 results showed potential safety and efficacy of etripamil in 104 patients with PSVT.
314. Prognosis and the Effect of De-Escalation of Antiplatelet Therapy After Nuisance Bleeding in Patients With Myocardial Infarction.
作者: Eun Ho Choo.;Ik Jun Choi.;Sungmin Lim.;Donggyu Moon.;Chan Joon Kim.;Mahn-Won Park.;Min Chul Kim.;Byung-Hee Hwang.;Kwan Yong Lee.;Yun Seok Choi.;Hee-Yeol Kim.;Ki-Dong Yoo.;Doo Soo Jeon.;Youngkeun Ahn.;Kiyuk Chang.; .
来源: Circ Cardiovasc Interv. 2022年15卷12期e012157页
Data regarding prognosis and management after nuisance bleeding (NB) is limited. The purpose was to examine the prognostic significance of NB in patients receiving potent dual antiplatelet treatment (DAPT) after acute myocardial infarction and the impact of de-escalation of DAPT on clinical outcomes thereafter.
315. Impact of Udenafil on Echocardiographic Indices of Single Ventricle Size and Function in FUEL Study Participants.
作者: Michael V Di Maria.;David J Goldberg.;Victor Zak.;Chenwei Hu.;Adam M Lubert.;Andreea Dragulescu.;Andrew S Mackie.;Andrew McCrary.;Angela Weingarten.;Anitha Parthiban.;Benjamin Goot.;Bryan H Goldstein.;Carolyn Taylor.;Christopher Lindblade.;Christopher J Petit.;Christopher Spurney.;David M Harrild.;Elaine M Urbina.;Eleanor Schuchardt.;Gi Beom Kim.;Ja Kyoung Yoon.;Jamie N Colombo.;Matthew D Files.;Megan Schoessling.;Peter Ermis.;Pierre C Wong.;Ruchira Garg.;Sara K Swanson.;Shaji C Menon.;Shubhika Srivastava.;Thor Thorsson.;Tiffanie R Johnson.;Usha S Krishnan.;Stephen M Paridon.;Peter C Frommelt.; .
来源: Circ Cardiovasc Imaging. 2022年15卷11期e013676页
The FUEL trial (Fontan Udenafil Exercise Longitudinal) demonstrated statistical improvements in exercise capacity following 6 months of treatment with udenafil (87.5 mg po BID). The effect of udenafil on echocardiographic measures of single ventricle function in this cohort has not been studied.
316. Magnetic Resonance Imaging of Intraplaque Hemorrhage and Plaque Lipid Content With Continued Lipid-Lowering Therapy: Results of a Magnetic Resonance Imaging Substudy in AIM-HIGH.
作者: Xue-Qiao Zhao.;Jie Sun.;Daniel S Hippe.;Daniel A Isquith.;Gador Canton.;Kiyofumi Yamada.;Niranjan Balu.;John R Crouse.;Todd J Anderson.;John Huston.;Kevin D O'Brien.;Thomas S Hatsukami.;Chun Yuan.; .
来源: Circ Cardiovasc Imaging. 2022年15卷11期e014229页
Intraplaque hemorrhage (IPH) is associated with plaque progression and ischemic events, and plaque lipid content (% lipid core) predicts the residual atherosclerotic cardiovascular disease risk. This study examined the impact of IPH on lipid content change in the setting of intensive lipid-lowering therapy.
317. Experiences Implementing a Suite of Decision Aids for Implantable Cardioverter Defibrillators: Qualitative Insights From the DECIDE-ICD Trial.
作者: Christopher E Knoepke.;Bryan C Wallace.;Larry A Allen.;Carmen L Lewis.;Sanjaya K Gupta.;Pamela N Peterson.;Daniel B Kramer.;Scott C Brancato.;Paul D Varosy.;John M Mandrola.;Wendy S Tzou.;Daniel D Matlock.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷11期e009352页
Shared decision making (SDM) is gaining importance in cardiology, including Centers for Medicare & Medicaid Services (CMS) reimbursement policies requiring documented SDM for patients considering primary prevention implantable cardioverter defibrillators. The DECIDE-ICD Trial (Decision Support Intervention for Patients offered implantable Cardioverter-Defibrillators) assessed the implementation and effectiveness of patient decision aids (DAs) using a stepped-wedge design at 7 sites. The purpose of this subanalysis was to qualitatively describe electrophysiology clinicians' experience implementing and using the DAs.
318. Improvements and Maintenance of Clinical and Functional Measures Among Rural Women: Strong Hearts, Healthy Communities-2. 0 Cluster Randomized Trial.
作者: Rebecca A Seguin-Fowler.;Galen D Eldridge.;Chad D Rethorst.;Meredith L Graham.;Margaret Demment.;David Strogatz.;Sara C Folta.;Jay E Maddock.;Miriam E Nelson.;Seungyeon Ha.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷11期e009333页
Cardiovascular disease is the leading cause of death in the United States; however, women and rural residents face notable health disparities compared with male and urban counterparts. Community-engaged programs hold promise to help address disparities through health behavior change and maintenance, the latter of which is critical to achieving clinical improvements and public health impact.
319. Quality of Life Trajectory and Its Mediators in Older Patients With Acute Decompensated Heart Failure Receiving a Multi-Domain Rehabilitation Intervention: Results From the Rehabilitation Therapy in Older Acute Heart Failure Patients Trial.
作者: David Whellan.;Melissa M McCarey.;Haiying Chen.;M Benjamin Nelson.;Amy M Pastva.;Pamela Duncan.;Robert J Mentz.;Dalane W Kitzman.;Gordon Reeves.;Shelby D Reed.
来源: Circ Heart Fail. 2022年15卷12期e009695页
As patients with heart failure experience worsening of their condition, including acute decompensated heart failure, quality of life deteriorates. However, the trajectory of quality of life changes and their determinants in the context of the Rehabilitation Therapy in Older Acute Heart Failure Patients trial physical rehabilitation intervention are unknown.
320. Incidental Coronary Artery Calcium: Opportunistic Screening of Previous Nongated Chest Computed Tomography Scans to Improve Statin Rates (NOTIFY-1 Project).
作者: Alexander T Sandhu.;Fatima Rodriguez.;Summer Ngo.;Bhavik N Patel.;Domenico Mastrodicasa.;David Eng.;Nishith Khandwala.;Sujana Balla.;Doug Sousa.;David J Maron.
来源: Circulation. 2023年147卷9期703-714页
Coronary artery calcium (CAC) can be identified on nongated chest computed tomography (CT) scans, but this finding is not consistently incorporated into care. A deep learning algorithm enables opportunistic CAC screening of nongated chest CT scans. Our objective was to evaluate the effect of notifying clinicians and patients of incidental CAC on statin initiation.
|